Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats

Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats

Objective(s): Diabetes mellitus (DM) affects the pharmacokinetics of drugs. Ranolazine is an antianginal drug that is prescribed in DM patients with angina. We decided to evaluate the effect of DM on the pharmacokinetics of ranolazine and its major metabolite CVT-2738 in rats.Materials and Methods:...

Full description

Bibliographic Details
Main Authors:	Habibeh Mashayekhi-sardoo, Hossein Kamali, Soghra Mehri, Amirhossein Sahebkar, Mohsen Imenshahidi, Amir Hooshang Mohammadpour
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2022-07-01
Series:	Iranian Journal of Basic Medical Sciences
Subjects:	clearance diabetes mellitus pharmacokinetics ranolazine volume of distribution
Online Access:	https://ijbms.mums.ac.ir/article_20646_6b6322fe9f40ebe8877e67759568761c.pdf

Similar Items

Pharmacokinetic study of ranolazine in Chinese healthy volunteers
by: YU Mingjie, et al.
Published: (2019-01-01)

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis
by: Bridget A. Scoville, et al.
Published: (2019-01-01)

Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes
by: Velia Cassano, et al.
Published: (2022-12-01)

Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
by: Gopal Chandra Ghosh, et al.
Published: (2018-01-01)

Update on evidence for treatment with ranolazine in stable angina
by: Federico Carbone, et al.
Published: (2013-10-01)

Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture
by: Adrián Jordá, et al.
Published: (2022-10-01)

Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function
by: Nishant R. Shah, et al.
Published: (2017-05-01)

A case of vasospastic angina. Vasospasm physiopathology: a new therapeutic role for ranolazine?
by: Carlo Uran, et al.
Published: (2020-08-01)

Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis
by: Athanasios Manolis, et al.
Published: (2023-05-01)

Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoprotein
by: Faisal Alotaibi
Published: (2023-03-01)

The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation
by: Fausto Devecchi, et al.
Published: (2008-08-01)

Improvement of Vascular Insulin Sensitivity by Ranolazine
by: Sol Guerra-Ojeda, et al.
Published: (2023-08-01)

Extended-release ranolazine: critical evaluation of its use in stable angina
by: Melloni C, et al.
Published: (2011-08-01)

RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial
by: Sandhiya Selvarajan, et al.
Published: (2015-01-01)

Place of the novel drug ranolazine in the treatment of coronary artery disease
by: GA Baryshnikova, et al.
Published: (2014-12-01)

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure
by: Gintautas Gumbrevičius, et al.
Published: (2019-12-01)

Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation
by: Julian Wolfes, et al.
Published: (2020-10-01)

Ranolazine Counteracts Strength Impairment and Oxidative Stress in Aged Sarcopenic Mice
by: Alessio Torcinaro, et al.
Published: (2022-07-01)

Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention
by: Konstantinos Kourtis, et al.
Published: (2024-01-01)

Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia
by: Shereen M. Samir, et al.
Published: (2024-01-01)

Ranolazine Inhibits Pyroptosis via Regulation of miR-135b in the Treatment of Diabetic Cardiac Fibrosis
by: Long Ren, et al.
Published: (2022-01-01)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
by: James A. Coleman, et al.
Published: (2024-04-01)

Ranolazine as an additional antianginal therapy in patients with stable symptomatic coronary artery disease
by: Benjamín Sanfuentes, et al.
Published: (2018-11-01)

Effect of ranolazine on the course of ischemic heart disease after percutaneous coronary intervention
by: О.А. Yepanchintseva, et al.
Published: (2020-12-01)

Impact of ranolazine on ventricular arrhythmias – A systematic review
by: George Bazoukis, et al.
Published: (2018-04-01)

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
by: Gennaro Riccio, et al.
Published: (2018-02-01)

Ranolazine treatment for refractory angina in a patient with Hutchinson-Gilford progeria syndrome and end stage aortic stenosis
by: Giuseppe Limongelli, et al.
Published: (2020-01-01)

Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3
by: Reina Bianca Tan, MD, et al.
Published: (2017-01-01)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
by: Kim Dao, et al.
Published: (2020-02-01)

Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
by: Alice Mezincescu, et al.
Published: (2018-04-01)

Ranolazine-Mediated Attenuation of Mechanoelectric Feedback in Atrial Myocyte Monolayers
by: Irene Del-Canto, et al.
Published: (2020-08-01)

Ranolazine Interacts Antagonistically with Some Classical Antiepileptic Drugs—An Isobolographic Analysis
by: Kinga Borowicz-Reutt, et al.
Published: (2022-12-01)

Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations
by: Aziz Unnisa, et al.
Published: (2023-08-01)

Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis
by: Chintan Trivedi, MD, MPH, et al.
Published: (2017-06-01)

Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study
by: Christoforos Olympios, et al.
Published: (2024-03-01)

Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials
by: Pattranee Leelapatana, et al.
Published: (2021-04-01)

The use of ranolazine in the treatment of coronary heart disease
by: V. S Zadionchenko, et al.
Published: (2014-12-01)

Ranolazine improved left ventricular diastolic functions and ventricular repolarization indexes in patients with coronary slow flow
by: Dogac Oksen, et al.
Published: (2023-08-01)

PHARMACOKINETIC RESEARCHES AND PRACTICAL MEDICINE
by: V. G. Belolipetskaya, et al.
Published: (2015-12-01)